HOME        CME INFORMATION        PROGRAM DIRECTORS        NEWSLETTER ARCHIVE        EDIT PROFILE        RECOMMEND TO A COLLEAGUE

VOLUME 3 - ISSUE 2 European Association for the Study of the Liver HCV Update Our guest author is Mark S. Sulkowski, MD, Professor of Medicine and Medical Director of the Viral Hepatitis Center, Divisions of Infectious Diseases and Gastroenterology/Hepatology at The Johns Hopkins University School of Medicine in Baltimore. After participating in this activity, the participant will demonstrate the ability to: Summarize the evidence describing newly emerging therapies for hepatitis C Assess how these newly emerging therapies may affect therapeutic decision-making in patients with HCV genotype 3 Assess how these new therapies may affect therapeutic decision-making in patients with HCV genotype 1 This discussion, offered as a downloadable audio file and companion transcript, covers advancements in hepatitis C therapy presented at EASL, as well as case-study scenarios for the clinical practice. This program is a follow up to the Volume 3, Issue 1 eViralHepatitis Review newsletter—European Association for the Study of the Liver (EASL)/HCV Update. Unlabeled/Unapproved Uses Dr. Sulkowski has indicated that in today's discussion he will be referencing the unapproved or non-indicated uses of sofosbuvir plus peginterferon/ribavirin (currently being reviewed by the FDA, but not yet approved), simeprevir plus peginterferon/ribavirin (also currently being reviewed by the FDA and not yet approved), interferon-free regimens including sofosbuvir plus daclatasvir and sofosbuvir plus ledipasvir, as well as other experimental interferon-free HCV treatment regimens, some including the addition of ritonavir. Mark S. Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and Gastroenterology/Hepatology The Johns Hopkins University School of Medicine Baltimore, Maryland Faculty Disclosure Dr. Sulkowski has indicated that he has received grant and or research support from AbbVie, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers-Squibb, Gilead, Janssen, Merck, and Vertex Pharmaceuticals Incorporated. He has served on consulting or advisory boards for AbbVie, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers-Squibb, Gilead, Janssen, Merck, and Vertex Pharmaceuticals Incorporated. And he has also served on a steering committee for Pfizer, Inc. Release Date September 26, 2013 Expiration Date September 25, 2015   Mark S. Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology The Johns Hopkins University School of Medicine Baltimore, Maryland Raymond T. Chung, MD Associate Professor of Medicine Harvard Medical School Director of Hepatology Vice Chief of Gastroenterology Massachusetts General Hospital Boston, Massachusetts Julie McArthur, MS, CRNP Adult Nurse Practitioner Division of Infectious Disease The Johns Hopkins University School of Medicine Baltimore, Maryland

Accreditation Statements Physicians This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Nurses The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity. credit designations Physicians eNewsletter: The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Podcast: The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses Newsletter: This 1 contact hour Educational Activity is provided by The Institute for Johns Hopkins Nursing. Each newsletter carries a maximum of 1 contact hour or a total of 6 hours for the six newsletters in this program. Podcast: This 0.5 contact hour Educational Activity is provided by the Institute for Johns Hopkins Nursing. Each podcast carries a maximum of 0.5 contact hours a total of 3 contact hours for the six podcasts in this program. Successful Completion To successfully complete this activity, participants must read the content, and then link to the Johns Hopkins University School of Medicine's website or the Institute for Johns Hopkins Nursing's website to complete the post-test and evaluation. Once you receive a passing grade, you can access and print your certificate of credit. NOTE: If you have already registered for other Hopkins CME programs on their prospective websites simply enter the requested information when prompted. There are no fees or prerequisites for this activity. This activity is supported by educational grants from AbbVie, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., and Genentech, Inc. Launch Date September 26, 2013; activities expire 2 years from the date of publication. Length of Activity: 30 minutes Internet CME Policy The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. The Johns Hopkins University SOM maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in an Internet-based CME program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine program. CME collects only the information necessary to provide you with the services that you request. Disclaimer Statement The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of the Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information for specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients. Statement of Responsibility The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity. Statement of Need Through discussions with experts in the specialty of HBV, a survey of participants from previous Johns Hopkins CME activities, and a review of current literature, the following core learning gaps have been identified: HCV Clinicians do not adequately identify which of their patients are at highest risk for HCV infection or effectively interpret testing results. Clinicians need to understand best practices in how to identify and manage HCV treatment-related side effects. Clinicians need improved awareness of how newly emerging therapies impact therapeutic decision-making in HCV infected and HIV/HCV co-infected patients. Clinicians are unaware of new non-invasive techniques to stage liver disease. Clinicians need to understand best practices in identifying cirrhosis and HCC in patients infected with HCV. HBV Clinicians do not effectively identify their patients at risk for HBV. Clinicians are unaware of new non-invasive techniques to stage liver disease. Clinicians need to understand best practices in identifying cirrhosis and HCC in patients infected with HBV. Intended Audience The target audience (clinicians) for the HBV curriculum includes: Primary: primary care physicians (PCPs), OB/GYNs, physician assistants (PAs), nurse practitioners (NPs), community gastroenterologists and others who care for patients of Asian and West African descent in areas of high HBV prevalence Secondary: gastroenterologists, infectious disease specialists, and other clinicians involved in the care of patients at risk for HBV The target audience for the HCV curriculum includes: PCPs, OB/GYNs, NPs, PAs, hepatologists, gastroenterologists, infectious disease physicians, and others involved in the care of patients with hepatitis. Planner disclosures As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships, regardless of their relevance to the activity content. Faculty are required to disclose only those relationships that are relevant to their specific presentations. The following relationships have been reported for this activity: Mark S. Sulkowski, MD, has disclosed that he has served as a consultant for AbbVie, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers-Squibb, Gilead, Janssen, Merck and Vertex Pharmaceuticals Incorporated. He has received grant/research funding from AbbVie, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers-Squibb, Gilead, Janssen, Merck and Vertex Pharmaceuticals Incorporated, and has served on a steering committee for Pfizer, Inc. Raymond T. Chung, MD, has disclosed that he has served as a consultant for AbbVie, Inc. and Idenix and has received grant/research funding from Gilead and Mass Biologics. No other planners have indicated that they have any financial interests or relationships with a commercial entity. Guest Author Disclosures Confidentiality Disclaimer for CME Conference Attendees I certify that I am attending a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes. I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person's health or treatment that identifies the person. I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu. "The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only." For CME Questions, please contact the CME Office at (410) 955-2959 or e-mail cmenet@jhmi.edu. Johns Hopkins University School of Medicine Office of Continuing Medical Education Turner 20/720 Rutland Avenue Baltimore, Maryland 21205-2195 Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03) Updated 4/09 hardware & software requirements Pentium 800 processor or greater, Windows 98/NT/2000/XP/7 or Mac OS 9/X, Microsoft Internet Explorer 5.5 or later, 56K or better modem, Windows Media Player 9.0 or later, 128 MB of RAM, sound card and speakers, Adobe Acrobat Reader, storage, Internet connectivity, and minimum connection speed. Monitor settings: High color at 800 x 600 pixels.

If you want to now listen to the eViralHepatitis Review podcast, just click on the button above. This will open your Internet browser to play the podcast by streaming the media via the web. Please note: This podcast file is large so please be patient while the content downloads. Save the podcast to your computer. Once saved you can manage and play the file like any song or music using your music software (iTunes, Windows Media, Real Player, etc.). You can also transfer the podcast file to your iPod, MP3 player and listen while on-the-go. Like any RSS subscription, when you subscribe to this Review you will automatically receive each new edition, downloaded to your hard drive as soon as it becomes available. You may manage and play the downloaded podcast file like any song or audio file by using your music software (iTunes, Windows Media, Real Player, etc.). You can also transfer the podcast file to your iPod, MP3 player to listen while on-the-go. COMPLETE THE POST-TEST Step 1. Click on the appropriate link below. This will take you to the post-test. Step 2. If you have participated in a Johns Hopkins on-line course, login. Otherwise, please register. Step 3. Complete the post-test and course evaluation. Step 4. Print out your certificate. »Download the podcast transcript »Go to the companion newsletter »Learn more about podcasting   Help other ID specialists and primary care clinicians find solutions to the diagnosis and treatment of viral hepatitis. Forward a link to the eViralHepatitis Review website to a colleague.